Meet us at the ESPEN Congress in Milan, 7–10 September!

Logo TauroLock Logo TauroPharm

TauroLock™

Safe solutions for central-venous catheters

Central-venous catheters (CVC) help patients in many different contexts – from dialysis and cancer treatment to parenteral nutrition. But while vascular access devices (VAD) can save lives, they can also lead to potentially life-threatening infections. 

 

TauroLock™ lock solutions prevent catheter-related complications by combining several effects in one product:

antimicrobial to avoid infections

antibiofilm to keep catheters clean

antiocclusive to maintain a good flow rate

Our product range includes different variants to meet the patients’ individual needs. The main active ingredients (used in varying compositions) are taurolidine, heparin, citrate, and urokinase

Why do you need a catheter lock solution?

If a CVC system does not remain completely sanitary at all times, it can cause dangerous infections. It is also important to avoid the formation of biofilm, a three-dimensional matrix for germs. So, how can we protect central-venous catheters against those complications? Our answer: TauroLock™. Unlike traditional lock solutions, we rely on a combination of active ingredients to ensure multiple effects at once.

Taurolidine is antimicrobial

It kills more than 500 germs without generating resistance. This includes MRSA (methicillin-resistentant staphylococcus aureus) and VRE (vancomycin-resistant enterococci).


 

Heparin and citrate
are anticoagulant

They prevent occlusions and sustain an adequate flow rate.


 

Urokinase is fibrinolytic

It can break up blood clotting in its early stages.

Taurolock-Hep500-Vials

Used in the right concentration, these four substances provide the basis for a lock solution that effectively prevents catheter-related bloodstream infections (CRBSI) and occlusions.  

When do you need TauroLock™ solutions?

Our products are suitable for a variety of patients. We recommend TauroLock™ solutions for all central access devices (CAD), such as those needed in:

Dialysis

Patients who depend on extracorporeal blood cleansing due to permanent kidney failure can use TauroLock™-HEP500, TauroLock™-U25.000, or TauroLock™.

Oncology

Patients who undergo treatments such as chemotherapy to fight cancer can use TauroLock™, TauroLock™-HEP100, or TauroLock™-U25.000.

Parenteral nutrition

Patients who must be fed through a central-venous catheter can use TauroLock™, NutriLock™, TauroLock™-HEP100, or TauroLock™-U25.000.

Intensive care units

Patients in ICU can be treated with TauroLock™ or TauroLock™-HEP100, according to their medical condition.

Product Ingredients Recommended Fields of Application
  • taurolidine
  • 4 % citrate
  • dialysis
  • oncology
  • parenteral nutrition
  • ICU
  • taurolidine
  • 4 % citrate
  • 100 IU/ml of heparin
  • oncology
  • parenteral nutrition
  • ICU
  • taurolidine
  • 4 % citrate
  • 500 IU/ml of heparin
  • dialysis
  • taurolidine
  • 4 % citrate
  • 25,000 IU of urokinase
  • dialysis
  • oncology
  • parenteral nutrition
  • taurolidine
  • parenteral nutrition

Each catheter lock solution from our TauroLock™ range has proven safe and efficient. Testings have shown that taurolidine has a good biocompatibility and clinical tolerability: Once the substance enters the body through the VAD, it degrades to taurine (amino acid), carbon dioxide, and water.  

More about our lock solutions

On our website, you can find detailed information about the usage and benefits of TauroLock™ products. Any particular questions or concerns? We are happy to help, feel free to contact us anytime:

Studies on the efficacy of lock solutions

Study by Torres-Viera et al.

“In vitro, the antimicrobial agent taurolidine inhibited virtually all of the bacteria tested, including vancomycin-resistant enterococci, oxacillin-resistant staphylococci, and Stenotrophomonas maltophilia, at concentrations between 250 and 2,000 mg/ml. Taurolidine was not effective in experimental endocarditis. While it appears unlikely that this antimicrobial would be useful for systemic therapy, its bactericidal activity and the resistance rates found (<10-9) are favorable indicators for its possible development for topical use.”

Study by Hogan et al.

“…The antiseptics ethanol and Taurolock were shown to be most effective at inactivating biofilm; this was evident against all stages of biofilm investigated...“

For personal inquiries, feel free to contact us via phone or email.

Our international distributors based in more than 50 countries will answer your requests ASAP.

TauroLock™

Newsletter

We'll keep you posted on upcoming events, free download materials, and research insights.